Practice pointer: Practical management of coagulopathy associated with warfarin

BMJ (Online)

Volumn 340, Issue 7752, 2010, Pages 918-

  Garcia, David ^a   Crowther, Mark A ^b   Ageno, Walter ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; DISEASE EXACERBATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS; CHEMICALLY INDUCED DISORDER; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK FACTORS; VITAMIN K; WARFARIN;

EID: 77951580526     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1813     Document Type: Review

References (18)

1. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006;47:804-808[Abstract/Free Full Text] (Pubitemid 43243105)
2. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008;133(suppl):257- 98S.[CrossRef]
3. Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998;103:422-424[CrossRef][Web of Science] [Medline] (Pubitemid 28522448)
4. Crowther MA, Julian J, Douketis JD, Kovacs M, Biagoni L, Schnurr T, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized clinical trial. Lancet 2000;356:1551-1553 [CrossRef][Web of Science][Medline]
5. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20:1159-1166[CrossRef][Web of Science][Medline]
6. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol 2005;46:732-733[Free Full Text] (Pubitemid 41132707)
7. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150:293-300. [Abstract/Free Full Text]
8. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400.[Abstract/Free Full Text] (Pubitemid 32845864)
9. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res 2004;113:205-209[CrossRef][Web of Science][Medline] (Pubitemid 38609405)
10. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893-900. [Abstract/Free Full Text]
11. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168:63-69[Abstract/Free Full Text]
12. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008;83:639-645[Abstract/Free Full Text]
13. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998;79:1116-1118[Web of Science] [Medline] (Pubitemid 28297157)
14. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008;83:137-143 [CrossRef][Web of Science][Medline]
15. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;349:675-683[Free Full Text] (Pubitemid 36980605)
16. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008:36-38
17. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin k antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008;133:160-98S.[CrossRef] (Pubitemid 351892967)
18. Baglin T, Keeling D, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br J Haematol 2006;132:277- 285[CrossRef][Web of Science][Medline]